ESR1 and breast cancer: In ERα-positive cells, estradiol can inhibit Notch activity and affect expression as well as cellular distribution of NOTCH1. Unfortunately, tamoxifen and raloxifene can reactivate Notch activity in ERα-positive breast cancer cells, leading to tamoxifen resistance [74].